Table 2 Cytokine expression of TNF-α, IL-6, IL-10 for different stimulation conditions in patients with neovascular AMD or geographic atrophy (GA) and a control series.
Controls (N = 30) | Neovascular AMD (N = 27) | GA (N = 24) | P value | |
|---|---|---|---|---|
Non-treated | ||||
TNF-α | 6.03 (4.01–7.23) | 5.37 (3.77–7.06) | 5.98 (4.84–6.97) | 0.55 |
IL-6 | 4.71 (2.22–6.34) | 4.23 (2.61–5.24) | 4.35 (2.79–6.55) | 0.34 |
IL-10 | 7.69 (6.08–8.23) | 6.82 (4.85–8.86) | 8.10 (6.74–9.41) | 0.36 |
LPS-treated | ||||
TNF-α | 194 (72–270) | 187 (112–436) | 241 (162–306) | 0.54 |
IL-6 | 668 (188–1212) | 461 (143–870) | 765 (210–1716) | 0.78 |
IL-10 | 24.6 (4.77–41.8) | 12.7 (8.21–36.1) | 21.7 (8.50–59.0) | 0.18 |
CML-treated | ||||
TNF-α | 6.39 (4.07–11.5) | 6.20 (3.11–10.3) | 4.95 (2.84–8.73) | 0.60 |
IL-6 | 3.20 (1.28–10.7) | 1.63 (0.77–4.48) | 2.69 (1.26–6.72) | 0.09 |
IL-10 | 5.50 (1.13–8.41) | 2.16 (1.13–5.04) | 3.23 (1.57–6.95) | 0.10 |
A2E-treated | ||||
TNF-α | 1.02 (0.76–1.80) | 1.27 (0.74–1.45) | 1.19 (0.80–1.83) | 0.92 |
IL-6 | 1.91 (0.75–4.42) | 1.33 (0.66–2.77) | 1.00 (0.67–2.58) | 0.45 |
IL-10 | 1.98 (0.41–6.69) | 2.74 (0.83–4.94) | 1.47 (0.83–4.76) | 0.89 |
